[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368493-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368493-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-characteristics-of-transgender-patients-with-breast-cancer-a-single-institution-experience","Clinical characteristics of transgender patients with breast cancer - a single institution experience","","Retrospective institutional study describing breast cancer features in 14 transgender and nonbinary patients treated at a specialized transgender health center from 2016–2023. Patients had a median age of 53 years, and 86% were 40+ and eligible for screening mammography. Six were trans men, seven trans women, and one genderqueer. Distribution included ductal/lobular carcinoma in situ and stages 1–2, with implant-associated lymphoma. Biomarkers showed 67% ER-positive and 33% ER-negative disease. Findings emphasize underused screening mammography and diverse subtypes in an underserved population.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-characteristics-of-transgender-patients-with-breast-cancer-a-single-institution-experience/368493/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-characteristics-of-transgender-patients-with-breast-cancer-a-single-institution-experience/368493.png","ImageObject",300,407,{"name":42,"@type":43},"Aria Callaghan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were patients identified and included in the study?","Question",{"text":63,"@type":64},"Patients were identified from electronic records between Jan 2016 and Mar 2023 using codes for breast cancer and gender identity disorders or related complaints. Inclusion required a transgender, gender nonbinary, or genderqueer patient with breast cancer in situ or malignant breast neoplasm and complete records.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the key findings about detection and presentation of breast cancer?",{"text":68,"@type":64},"Cancer was detected through screening mammography in 29%, self-palpation of a breast or axillary mass in 43%, and breast imaging mandated before planned chest masculinization surgery in 29%. Half the cohort was eligible for routine screening mammography, yet screening captured a minority of diagnoses.",{"name":70,"@type":61,"acceptedAnswer":71},"What biomarker and hormone therapy patterns were observed?",{"text":72,"@type":64},"Sixty-seven percent of cancers were estrogen receptor (ER)-positive and 33% ER-negative. Fifty percent of patients had estrogen-based GAHT and 50% had testosterone-based GAHT, with a mean GAHT duration of 16.6 years overall.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368493,1790465785,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":30,"preview_urls":145},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Clinical characteristics of transgender patients with breast cancer: a single institution experience  \nEthan Ravetch1,‡, Nithya Krishnamurthy2,‡,*,, Christina Weltz3, Joshua D. Safer4  \n1Department of Surgery, Division of Breast Surgery, Montefiore Medical Center, Montefiore Breast Care Center, New York, NY, United States 2 Icahn School of Medicine at Mount Sinai, New York, NY, United States  \n3Dubin Breast Center at Mount Sinai, New York, NY, United States  \n4Center for Transgender Medicine and Surgery, Mount Sinai Health System, New York, NY, United States  \n* Corresponding author: Nithya Krishnamurthy, BA, Icahn School of Medicine at Mount Sinai 1 Gustave L. Levy Pl, New York, NY 10029, United States (nithya. [krishnamurthy@icahn.mssm.edu](krishnamurthy@icahn.mssm.edu)) .  \n‡Both co-first authors (N. K. and E. R. ) contributed equally to this manuscript.  \nAbstract  \nBreast cancer presents unique complexities for transgender individuals. This retrospective study characterized breast cancers in 14 transgender and nonbinary patients treated at a specialized transgender health center from 2016 to 2023. Patients with a median age of 53 (31–65 years) were identified using international classification of disease-10 codes. Most (86%) were aged 40 or older and eligible for screening mammography. The cohort included 6 trans men, 7 trans women, and one genderqueer individual. Diagnoses included ductal carcinoma in situ (36%), lobular carcinoma in situ (7%), stage 1 (29%), stage 2 (21%), and breast implant-associated anaplastic large cell lymphoma (7%) . Screening mammography diagnosed 29%, 43% presented with a mass, and 29% were detected during pre-surgical imaging. Half had estrogen-based gender-affirming hormone therapy (GAHT) and half testosterone-based, with mean GAHT durations of 16.6 years. Biomarker profiles revealed 67% estrogen receptor (ER)-positive and 33% ER-negative cancers. This study highlights underutilized screening mammography and diverse cancer subtypes in this underserved population.  \nKey words: transgender; breast cancer; screening; GAHT; biomarker.  \nIntroduction  \nBreast cancer presents unique complexities for transgender people, who encounter multifaceted barriers, including limited screening guidelines and gendered health practices.1 We aimed to characterize breast cancers in our transgender patients, focusing on biomarkers, diagnostic methods, stages, subtypes, and gender-affirming hormone therapy (GAHT) details.  \nMethods  \nThis institutional review board–approved study identified patients using electronic records (Jan 2016–Mar 2023), using Epic SlicerDicer to search for international classification of disease codes for breast cancer (D-05, C-50)2 and gender identity disorders (F-64)2 or transgender health-related complaints (N = 10 260). Inclusion criteria were patients who identified as transgender, gender nonbinary, or genderqueer and presented with breast cancer either in situ or malignant neoplasm of the breast. We identified 42 patients, 25 did not meet inclusion criteria,and 3 were excluded for incomplete records. Chart reviews were performed on the 14 patients who met the inclusion criteria.  \nPatient demographics  \nFourteen patients were identified, of whom 6 were trans men, 7 were trans women, and one was genderqueer (recorded  \nfemale at birth) . Four patients self-identified as AfricanAmerican, 8 as white, 1 as Hispanic, and 1 as unknown (Table 1) . The median age at diagnosis was 53 (31-65 years) and 86%(12/14) were at or above 40 years of age at diagnosis and eligible for routine screening mammography. Two patients had a first-degree relative with breast cancer, but tested negative for cancer-associated mutations.  \nGAHT use  \nFifty percent (7/14) of patients had an active or past prescription for testosterone-based GAHT, and 50%(7/14) of patients had estrogen-based GAHT. The mean duration of all GAHT at the time of analysis was 16.6 years (3-40 years), while the mean duration of feminizing G","cbCaibg6JDCjKmun","https://ap.wps.com/l/cbCaibg6JDCjKmun","pdf",159763,"English","# Abstract\n# Introduction\n# Methods\n# Patient demographics\n# GAHT use\n# Cancer diagnosis\n# Table 1. Clinical characteristics and demographic data","[{\"question\":\"How were patients identified and included in the study?\",\"answer\":\"Patients were identified from electronic records between Jan 2016 and Mar 2023 using codes for breast cancer and gender identity disorders or related complaints. Inclusion required a transgender, gender nonbinary, or genderqueer patient with breast cancer in situ or malignant breast neoplasm and complete records.\"},{\"question\":\"What were the key findings about detection and presentation of breast cancer?\",\"answer\":\"Cancer was detected through screening mammography in 29%, self-palpation of a breast or axillary mass in 43%, and breast imaging mandated before planned chest masculinization surgery in 29%. Half the cohort was eligible for routine screening mammography, yet screening captured a minority of diagnoses.\"},{\"question\":\"What biomarker and hormone therapy patterns were observed?\",\"answer\":\"Sixty-seven percent of cancers were estrogen receptor (ER)-positive and 33% ER-negative. Fifty percent of patients had estrogen-based GAHT and 50% had testosterone-based GAHT, with a mean GAHT duration of 16.6 years overall.\"}]","Clinical characteristics of transgender patients with breast cancer - a single institution experience | PDF",1790177224,[146,150,154],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7be086256a313bbad789eed741bdb7ea.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f976f617b7e16663544ff6d3798963c.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17c5cf0a2eeb866263fca339c14cb942.webp",981,1289]